2026-01-29 - Analysis Report
**ABBV Stock Analysis Report**
================================

### Company Overview
AbbVie is a multinational biopharmaceutical company developing and marketing treatments for various diseases and conditions.

### Return Rate Comparison
- Cumulative return of review stock: **186.19%**
- Cumulative return of comparison stock (S&P 500, VOO): **128.51%**
- Divergence (relative divergence): **71.50%**

### Alpha, Beta Analysis
| Period  | CAGR | MDD  | Alpha | Beta | Market Capitalization |
|---------|------|------|-------|------|------------------------|
| 2016-2018 | 35.0% | 23.1% | 26.0% | 1.0 | $158.9B |
| 2017-2019 | 27.0% | 23.1% | 2.0% | 1.1 | $152.6B |
| 2018-2020 | -19.0% | 32.9% | -43.0% | 0.8 | $184.7B |
| 2019-2021 | 77.0% | 32.9% | 13.0% | 0.7 | $233.4B |
| 2020-2022 | 100.0% | 32.9% | 96.0% | 0.6 | $278.5B |
| 2021-2023 | 54.0% | 19.5% | 36.0% | 0.4 | $267.1B |
| 2022-2024 | 33.0% | 19.5% | 4.0% | 0.3 | $306.3B |
| 2023-2025 | 84.0% | 20.4% | 9.0% | 0.3 | $393.8B |

### Recent Stock Price Fluctuations
- Close: **$223.93**
- Last-market: **$218.415 (-2.46%)**
- 5-day SMA: **$219.64**
- 20-day SMA: **$222.31**
- 60-day SMA: **$224.91**

### Indicator Analysis
- Market Risk Indicator (MRI): **0.70**
- RSI: **50.00**
- PPO: **0.11**
- Expected Return (%): **23.50%**
- Recent relative divergence change: **+5.60**

### Recent News & Significant Events
- AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth
- US names HIV, arthritis drugs for next Medicare price talks
- Goldman Sachs maintains Neutral rating on Abbvie stock ahead of 2026 guidance
- AbbVie Rose 2% Last Week. Hereâ€™s Why It Could Deliver 14% Upside In 2026
- Citigroup Issues Pessimistic Forecast for AbbVie (NYSE:ABBV) Stock Price
- AbbVie, SLB, Amphenol, And More On CNBC's 'Final Trades'

### Analyst Opinions
*Analyst Consensus:*
*   Key: Buy
*   Mean (1=StrongBuy~5=Sell): 1.93 (~Buy)
*   Opinions: 27
*   Target Price (avg/high/low): 245.04 / 289.00 / 184.00

### Comprehensive Analysis
Considering the cumulative return of 186.19% and relative divergence of 71.50%, ABBV stock has outperformed the S&P 500 in the given period. The recent stock price fluctuations indicate a minor decline of 2.46%. The indicator analysis shows a neutral Market Risk Indicator (MRI) of 0.70, RSI of 50.00, and PPO of 0.11. The Expected Return is 23.50%. The recent news and significant events suggest positive and negative opinions from analysts, with the majority recommending a "Buy" with a mean rating of 1.93. Overall, ABBV stock appears to be a promising investment opportunity, but investors should remain cautious due to the recent pessimistic forecast from Citigroup.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.